MD-PATTON-ELECTRONICS
13.9.2016 15:04:14 CEST | Business Wire | Press release
Patton Electronics —US manufacturer of UC, cloud, and IoT enabling solutions for carrier, enterprise and industrial networks—is now shipping a new line of cost-effective, high-performance SmartNode enterprise session border controllers (eSBC) that offer two to eight integrated telephony interfaces.
A typical eSBC provides All-IP, SIP-to-SIP communication only , whereas conversion from traditional analog or ISDN to IP telephony remains the job of a separate VoIP Media gateway. By merging media gateway functions with high-end eSBC capabilities in a single, low-cost, customer-premise device, Patton’s innovation accelerates obsolesce of the traditional Analog Telephone Adapter (ATA).
The new VoIP CPE are designed for small-businesses/small-offices that need to integrate legacy phones, fax machines, meters, postage machines, or POTS/ISDN trunks into ALL-IP communication systems, including on-premise and hosted UC solutions.
The SN5541 offers 2, 4 or 8 FXS ports . The SN4151 offers flexible combinations of 2 to 8 FXS & BRI ports.
“The world is going ALL-IP,” said Burton A. Patton, EVP. “Cloud Telephony remains on the rise. In order to achieve convergence, many enterprises proliferate their on-premise devices. In one box, a Patton eSBC does the job of two, three, or more devices—at half the cost of alternative solutions.”
For businesses with immediate FXS/BRI media conversion requirements: Patton’s SmartNode 4141 VoIP gateway has got you covered. Offering license-key conversion to rich-featured eSBC functionality, the SN4141 also supports inevitable migration to SIP-trunking, unified communications (UC), hosted or cloud-based services.
Carrier Class. Patton’s carrier-grade dual image feature—rarely found in low-port-count CPE—provides fallback/recovery capability for service continuity during network-wide software upgrade.
Fully Loaded. New SmartNode eSBCs include such state-of-the-art features as SRTP/TLS security, USB cell-modem support, PSTN redundancy, 3G/4G fail-over/survivability, generic routing encapsulation (GRE tunneling), border gateway protocol (BGP).
They also boast the VoIP industry’s longest-reach FXS local loop (10 kilometers at 3 REN)—useful for such applications as off-premise extension.
A built-in BroadSoft PacketSmart Probe for network-monitoring is available.
Last month Patton announced CopperLink™ 1101 PoE Extender kits that leverage copper or coaxial cable to deliver Power-over-Ethernet up to 3,000 feet.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160913005076/en/
Contact:
Patton
Glendon Flowers, +1 301-975-1000
press@patton.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom